Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Finnzymes Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has completed its acquisition of Finnzymes for an undisclosed sum.

Espoo, Finland-based Finnzymes makes reagents, consumables, kits, and instruments for molecular biology applications. Its proprietary DNA polymerases, called Phire and Phusion, and high-speed miniaturized thermal cyclers will expand Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets.

Thermo announced the deal to acquire Finnzymes early last month. The acquired firm had full-year 2009 revenues of $20 million and will be integrated into Thermo Fisher's Analytical Technologies segment.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.